Abstract 799P
Background
Cisplatin-based chemotherapy is the treatment of choice in metastatic urothelial cancer (mUC). Nevertheless, about 50% of patients do not receive this treatment. Recently, specific criteria for unfitness-for-cisplatin (UFC) have been published. We used a multinational database to study the impact of adherence to UFC criteria in the outcome of unselected mUC patients
Methods
Selection criteria: diagnosis of mUC, transitional, mixed, squamous and adeno histologies, survival data available. Major end point: Overall survival (OS). UFC was defined according to Galsky et al (2011).
Results
From 1828 mUC patients 441 (24%) did not receive any chemotherapy. These patients had a significantly shorter median OS (Table). 1361 patients (median fup: 31 months) were included in the analysis of the following treatment types: cisplatin-based (689;50%), carboplatin-based (404;30%), no cis- or carbo-platin [other (268;20%)]. Cisplatin therapy was associated with longer OS (Table). 971 patients had full data regarding UFC. The following deviations from the UFC criteria were noted: 21% and 32% of the carboplatin and the other groups were fit-for-cisplatin, while 38% of the cisplatin-treated patients fulfilled at least one UFC criterion. UFC patients had inferior outcome. This effect was significant only in cisplatin-treated patients (Table), while the benefit from cisplatin was also more pronounced within the fit-for-cisplatin patients. This cisplatin therapy-UFC interaction was significant (p = 0.0343)
| Median OS (months) | 95% CI | p | |
|---|---|---|---|
| 1st-line chemotherapy Yes (n = 1499) No (n = 475) | 14.6 5.1 | 13.4-15.5 4.2-6.2 | ConclusionsA sizable proportion of fit-for-cisplatin patients do not receive cisplatin-based chemotherapy. Use of cisplatin for those patients may have potential to improve outcomes. On the contrary, unfit-for-cisplatin patients have a worse outcome and more efficient therapies should be sought. Clinical trial identificationLegal entity responsible for the studyN/A FundingIcahn School of Medicine at Mount Sinai, USA DisclosureAll authors have declared no conflicts of interest. Resources from the same sessionZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|